Payment overview · 2025
General Payments
$928.75
54 reported records · 19 companies
Healthcare provider profile · identity verified
Helen C Daniel-Glave, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LONGVIEW, TX · NPI 1467689158
Verified facts
What the public records show
CMS Open Payments records show Helen C Daniel-Glave, MD received $928.75 in general payments during 2025 across 54 reported records.
Novo Nordisk Inc accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $154.45 | 16.6% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.91 | 15.0% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $111.83 | 12.0% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $99.83 | 10.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.41 | 6.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.98 | 5.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.85 | 4.7% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.83 | 4.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.70 | 4.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.57 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.42 | 3.5% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $22.76 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.75 | 2.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $16.86 | 1.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.89 | 1.6% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $14.54 | 1.6% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $14.32 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.96 | 1.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.89 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $928.75 | 54 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $154.45 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $154.45 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $115.36 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $111.83 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $99.83 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.68 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $55.41 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $51.92 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.85 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.85 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.83 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $37.93 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.70 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.57 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $32.42 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.55 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 83 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
96 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
83 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 599 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 459 | 124 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 413 | 66 |
| Alprazolam | Alprazolam | 394 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 344 | 92 |
| Gabapentin | Gabapentin | 309 | 90 |
| Potassium Chloride | Potassium Chloride | 304 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 278 | 79 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 271 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 257 | 83 |
| Montelukast Sodium | Montelukast Sodium | 249 | 87 |
| Simvastatin | Simvastatin | 205 | 63 |
| Omeprazole | Omeprazole | 202 | 55 |
| Tramadol Hcl | Tramadol Hcl | 199 | 46 |
| Trazodone Hcl | Trazodone Hcl | 198 | 59 |
| Furosemide | Furosemide | 177 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 48 |
| Losartan Potassium | Losartan Potassium | 171 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 39 |
| Atenolol | Atenolol | 160 | 45 |
| Lisinopril | Lisinopril | 145 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 50 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 134 | 34 |
| Meloxicam | Meloxicam | 132 | 42 |
| Ozempic | Semaglutide | 131 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 130 | 27 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 36 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 124 | 33 |
| Allopurinol | Allopurinol | 120 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 117 | 35 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 114 | 35 |
| Carvedilol | Carvedilol | 111 | 32 |
| Jardiance | Empagliflozin | 110 | 27 |
| Glimepiride | Glimepiride | 108 | 32 |
| Pregabalin | Pregabalin | 108 | 31 |
| Telmisartan | Telmisartan | 106 | 31 |
| Clonazepam | Clonazepam | 105 | 15 |
| Famotidine | Famotidine | 104 | 34 |
| Memantine Hcl | Memantine Hcl | 102 | 32 |
| Metformin Hcl Er | Metformin Hcl | 101 | 33 |
| Mounjaro | Tirzepatide | 96 | 19 |
| Bupropion Xl | Bupropion Hcl | 90 | 20 |
| Metformin Hcl | Metformin Hcl | 88 | 30 |
| Doxazosin Mesylate | Doxazosin Mesylate | 86 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 84 | 24 |
| Eliquis | Apixaban | 83 | 17 |
| Prednisone | Prednisone | 83 | 67 |
| Cephalexin | Cephalexin | 82 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 82 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 23 |
| Sertraline Hcl | Sertraline Hcl | 80 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 18 |
| Mirtazapine | Mirtazapine | 79 | 27 |
| Aripiprazole | Aripiprazole | 78 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 23 |
| Ezetimibe | Ezetimibe | 75 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 25 |
| Clonidine Hcl | Clonidine Hcl | 72 | 22 |
| Temazepam | Temazepam | 72 | 14 |
| Buspirone Hcl | Buspirone Hcl | 71 | 24 |
| Lansoprazole | Lansoprazole | 71 | 18 |
| Celecoxib | Celecoxib | 65 | 24 |
| Spironolactone | Spironolactone | 63 | 16 |
| Azithromycin | Azithromycin | 62 | 52 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 61 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 58 | 18 |
| Donepezil Hcl | Donepezil Hcl | 57 | 20 |
| Doxepin Hcl | Doxepin Hcl | 52 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 14 |
| Raloxifene Hcl | Raloxifene Hcl | 52 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 50 | 20 |
| Methylprednisolone | Methylprednisolone | 50 | 44 |
| Paroxetine Hcl | Paroxetine Hcl | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 16 |
| Estradiol | Estradiol | 49 | 17 |
| Irbesartan | Irbesartan | 48 | 16 |
| Lorazepam | Lorazepam | 48 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 42 | 13 |
| Benazepril Hcl | Benazepril Hcl | 41 | 12 |
| Nifedipine Er | Nifedipine | 38 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Topiramate | Topiramate | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 35 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 22 |
| Fluconazole | Fluconazole | 33 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 28 |
| Primidone | Primidone | 32 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 32 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Diazepam | Diazepam | 30 | suppressed |
| Levofloxacin | Levofloxacin | 30 | 24 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Galantamine Er | Galantamine Hbr | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 17 |
| Glipizide | Glipizide | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Belsomra | Suvorexant | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 13 |
| Valacyclovir | Valacyclovir Hcl | 23 | 13 |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Klor-Con 10 | Potassium Chloride | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Np Thyroid | Thyroid,pork | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Trulance | Plecanatide | 17 | suppressed |
| Armour Thyroid | Thyroid,pork | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $928.75 · 54 records | Novo Nordisk Inc | AIRSUPRA, CAPVAXIVE, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, GARDASIL 9, Heplisav-B, JARDIANCE, Kerendia, Korlym, LEQVIO, NURTEC ODT, OFEV, OTEZLA, Ozempic, QULIPTA, REPATHA, REZDIFFRA, Rybelsus, Symbravo, TZIELD, Tymlos, UBRELVY, VOQUEZNA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error